Isthmus Partners LLC Purchases 7,001 Shares of OmniAb, Inc. (NASDAQ:OABI)

Isthmus Partners LLC lifted its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 1.6% during the 4th quarter, HoldingsChannel reports. The firm owned 453,135 shares of the company’s stock after acquiring an additional 7,001 shares during the period. Isthmus Partners LLC’s holdings in OmniAb were worth $1,604,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after buying an additional 5,751 shares during the period. Woodstock Corp grew its holdings in OmniAb by 1.2% in the fourth quarter. Woodstock Corp now owns 802,578 shares of the company’s stock worth $2,841,000 after purchasing an additional 9,725 shares during the period. Choreo LLC purchased a new stake in OmniAb in the fourth quarter worth about $41,000. FMR LLC increased its stake in shares of OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after purchasing an additional 13,324 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of OmniAb during the third quarter valued at approximately $61,000. 72.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on OABI. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reissued a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Stock Up 0.6 %

NASDAQ:OABI opened at $3.40 on Monday. The stock has a market cap of $480.13 million, a price-to-earnings ratio of -5.48 and a beta of -0.14. The company’s 50 day moving average price is $3.46 and its 200-day moving average price is $3.85. OmniAb, Inc. has a 52 week low of $3.10 and a 52 week high of $5.72.

Insider Activity at OmniAb

In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $82,584.36. Following the transaction, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew W. Foehr sold 41,811 shares of OmniAb stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the sale, the chief executive officer now owns 3,749,639 shares of the company’s stock, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,260 shares of company stock valued at $376,601. 8.60% of the stock is owned by corporate insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.